Transurethral Periprostatectomy Treatment of Cancerous Prostate Tissue
NCT: NCT07561502 · COMPLETED
Brief Summary
This goal of this clinical trial is to determine if the Vanquish System can safely and effectively treat cancerous tissue in the prostate. Researchers will also determine the best treatment dose, monitor safety during and immediately after the procedure, and examine prostate tissue after surgical removal to confirm how well the treatment destroyed targeted tissue. Patients enrolled have been diagnosed with prostate cancer and will undergo treatment with the Vanquish System before their scheduled radical prostatectomy.
Frequently Asked Questions
What is Transurethral Periprostatectomy Treatment of Cancerous Prostate Tissue?
Transurethral Periprostatectomy Treatment of Cancerous Prostate Tissue is a clinical trial registered under NCT07561502. Current status: COMPLETED.
What is the status of NCT07561502?
The current status of NCT07561502 (Transurethral Periprostatectomy Treatment of Cancerous Prostate Tissue) is: COMPLETED.
When did Transurethral Periprostatectomy Treatment of Cancerous Prostate Tissue start?
Transurethral Periprostatectomy Treatment of Cancerous Prostate Tissue started on 2022-11-14.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.